A prospective, pilot study to evaluate safety and efficacy of bortezomib and high-dose melphalan (Bor-HDM) conditioning regimen prior to autologous stem cell transplant (ASCT) in Japanese patients with newly diagnosed multiple myeloma

Trial Profile

A prospective, pilot study to evaluate safety and efficacy of bortezomib and high-dose melphalan (Bor-HDM) conditioning regimen prior to autologous stem cell transplant (ASCT) in Japanese patients with newly diagnosed multiple myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2015

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 14 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top